Klara Borgardts1, Johannes Menzel-Severing1, Gerd Geerling1, Theo G Seiler2,3,4. 1. Klinik für Augenheilkunde, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland. 2. Klinik für Augenheilkunde, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland. theo@seiler.tv. 3. Institut für Refraktive und Ophthalmo-Chirurgie (IROC), Stockerstr. 37, 8002, Zürich, Schweiz. theo@seiler.tv. 4. Klinik für Augenheilkunde, Universitätsspital Bern, Inselspital Bern, 3010, Bern, Schweiz. theo@seiler.tv.
Abstract
BACKGROUND: Corneal crosslinking (CXL) is used in keratoconus to strengthen and stabilize the cornea and to prevent further progression with subsequent visual loss and the possible need for keratoplasty. Correct treatment indications is crucial in this context. Since the introduction of the initial Dresden protocol, other modified CXL protocols have been proposed to optimize treatment success. OBJECTIVE: The relevant parameters for treatment indications are explained and the clinical results of new CXL protocols are presented. METHODS: The currently valid criteria with respect to the indications for CXL in keratoconus, PubMed search for relevant publications and own experiences with different CXL protocols are presented. RESULTS: The reproducibility of topographic parameters depends on the stage of the keratoconus. Accelerated CXL as well as transepithelial CXL with a hyperoxic environment show comparable efficiency with shorter surgery time and possibly lower complication rates. Customized CXL with an individualized UV irradiation profile provides improved results with faster epithelial healing. Lower UV energy doses enable CXL to be conducted in eyes with minimal stromal pachymetry of less than 400 µm before irradiation. The combination of CXL with photorefractive keratectomy (PRK) provides visual acuity improvements but also increases the risk of visual loss. CONCLUSION: Current indication rules for CXL neglect the reduced reproducability of topographic and tomographic measurements in keratoconus. The latest CXL protocols presented here provide a safe alternative with similar and/or better efficacy compared to standard CXL. The combination of CXL with PRK offers an option for visual rehabilitation in patients with contact lens intolerance.
BACKGROUND: Corneal crosslinking (CXL) is used in keratoconus to strengthen and stabilize the cornea and to prevent further progression with subsequent visual loss and the possible need for keratoplasty. Correct treatment indications is crucial in this context. Since the introduction of the initial Dresden protocol, other modified CXL protocols have been proposed to optimize treatment success. OBJECTIVE: The relevant parameters for treatment indications are explained and the clinical results of new CXL protocols are presented. METHODS: The currently valid criteria with respect to the indications for CXL in keratoconus, PubMed search for relevant publications and own experiences with different CXL protocols are presented. RESULTS: The reproducibility of topographic parameters depends on the stage of the keratoconus. Accelerated CXL as well as transepithelial CXL with a hyperoxic environment show comparable efficiency with shorter surgery time and possibly lower complication rates. Customized CXL with an individualized UV irradiation profile provides improved results with faster epithelial healing. Lower UV energy doses enable CXL to be conducted in eyes with minimal stromal pachymetry of less than 400 µm before irradiation. The combination of CXL with photorefractive keratectomy (PRK) provides visual acuity improvements but also increases the risk of visual loss. CONCLUSION: Current indication rules for CXL neglect the reduced reproducability of topographic and tomographic measurements in keratoconus. The latest CXL protocols presented here provide a safe alternative with similar and/or better efficacy compared to standard CXL. The combination of CXL with PRK offers an option for visual rehabilitation in patients with contact lens intolerance.
Authors: José A P Gomes; Donald Tan; Christopher J Rapuano; Michael W Belin; Renato Ambrósio; José L Guell; François Malecaze; Kohji Nishida; Virender S Sangwan Journal: Cornea Date: 2015-04 Impact factor: 2.651
Authors: Elke O Kreps; Marta Jimenez-Garcia; Ikram Issarti; Ilse Claerhout; Carina Koppen; Jos J Rozema Journal: Am J Ophthalmol Date: 2020-06-20 Impact factor: 5.258
Authors: Ingemar Gustafsson; Anders Bergström; Anna Cardiakides Myers; Anders Ivarsen; Jesper Hjortdal Journal: PLoS One Date: 2020-02-14 Impact factor: 3.240